Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galinpepimut-S in Multiple Myeloma Post-ASCT
NCT01827137Phase 2Completed
- Sponsor
- SELLAS Life Sciences Group, Inc.
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of galinpepimut-s in multiple myeloma (MM), sponsored by SELLAS Life Sciences Group, Inc.. Started Apr 2013; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01827137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827137.